Dermatology expert Linda Stein Gold, MD, explores the rationale for Janus kinase (JAK) inhibition in atopic dermatitis (AD), clinical trial data on approved and emerging JAK inhibitors in this setting, and the importance of considering JAK inhibitors when creating patient-specific plans for patients with inadequately controlled AD.
This program will address the evolving concepts of pathophysiology, diagnosis, and severity assessment of patients across a diverse spectrum of age, comorbidities, and skin of color. In conjunction, the role of new and emerging targeted therapy agents will be examined within the context of mild to severe AD.
How will you help a 5-year-old boy with a 6-month history of itchy, erythematous scaly patches and fissures on both feet? In 30 minutes, learn 5 important facts that will help you more accurately diagnose and manage mild to moderate pediatric atopic dermatitis in this on-demand activity.